Fiera Capital Corp Purchases 1,672 Shares of Cencora, Inc. (NYSE:COR)

Fiera Capital Corp boosted its position in shares of Cencora, Inc. (NYSE:COR) by 8.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,493 shares of the company’s stock after purchasing an additional 1,672 shares during the period. Fiera Capital Corp’s holdings in Cencora were worth $4,613,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in COR. Heritage Wealth Management Inc. bought a new position in Cencora in the 3rd quarter valued at $855,000. Summit Global Investments purchased a new stake in shares of Cencora during the third quarter valued at $297,000. Graypoint LLC grew its holdings in shares of Cencora by 7.8% in the third quarter. Graypoint LLC now owns 1,171 shares of the company’s stock worth $264,000 after purchasing an additional 85 shares during the last quarter. Concurrent Investment Advisors LLC increased its stake in Cencora by 12.1% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 7,697 shares of the company’s stock worth $1,732,000 after buying an additional 832 shares during the period. Finally, Maia Wealth LLC lifted its holdings in Cencora by 7.6% during the 3rd quarter. Maia Wealth LLC now owns 7,409 shares of the company’s stock valued at $1,742,000 after buying an additional 526 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

Shares of Cencora stock opened at $248.41 on Friday. Cencora, Inc. has a one year low of $191.11 and a one year high of $251.00. The company has a market capitalization of $48.95 billion, a PE ratio of 33.08, a P/E/G ratio of 1.55 and a beta of 0.44. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.55 and a current ratio of 0.88. The company has a 50-day simple moving average of $231.95 and a two-hundred day simple moving average of $230.79.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.89%. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. Cencora’s dividend payout ratio (DPR) is 27.16%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday. Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday. Bank of America restated a “neutral” rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.